6204 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 20
Goodwin et al.
References
(18) Kikucki, N.; Fujikura, H.; Tazawa, S.; Yamato, T.; Isaji, M.
Preparation of Pyrazole Glycoside Compounds as SGLT Inhibi-
tors. PCT Int. Appl. WO2004113359, 2004.
(19) Fujikura, H.; Fushimi, N.; Nishimura, T.; Nakabayashi, T.;
Isaji, M. Preparation of Glucopyranosylpyrazole Derivatives As
Inhibitors of Humans SGLT2 (Sodium-Dependent Glucose-
Transporter 2) Activity and Use Thereof in Medicines. PCT Int.
Appl. WO2002053573, 2002.
(20) Deshpande, P. P.; Ellsworth, B. A.; Singh, J.; Denzel, T. W.; Lai,
C.; Chiajen, G.; Randazzo, M. E.; Gougoutas, J. Z. Methods of
Producing C-Aryl Glucoside SGLT2 Inhibitors. U.S. Pat. Appl.
Pub. US2004138439, 2004.
(21) Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel,
M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller,
S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.;
Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.;
Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.;
Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.;
Washburn, W. N. Discovery of dapagliflozin: a potent, selective
renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibi-
tor for the treatment of type 2 diabetes. J. Med. Chem. 2008, 51,
1145–1149.
(22) Komoroski, B.; Vachharajani, N.; Feng, Y.; Li, L.; Kornhauser,
D.; Pfister, M. Dapagliflozin, a novel, selective SGLT2 inhibitor,
improved glycemic control over 2 weeks in patients with type 2
diabetes mellitus. Clin. Pharmacol. Ther. 2009, 85, 513–519.
(23) Komoroski, B.; Vachharajani, N.; Boulton, D.; Kornhauser, D.;
Geraldes, M.; Li, L.; Pfister, M. Dapagliflozin, a novel SGLT2
inhibitor, induces dose-dependent glucosuria in healthy subjects.
Clin. Pharmacol. Ther. 2009, 85, 520–526.
(24) List, J. F.; Woo, V.; Morales, E.; Tang, W.; Fiedorek, F. T.
Sodium-glucose cotransport inhibition with dapagliflozin in type
2 diabetes. Diabetes Care 2009, 32, 650–657.
(25) Nomura, S.; Kawanishi, E.; Ueta, K. Preparation of Glycosides as
Antidiabetic Agents and Having Inhibitory Activity against Sodium-
Dependent Transporter. PCT Int. Appl. WO2005012326, 2005.
(26) Abdel-Magid, A. F.; Chisholm, M.; Mehrman, S.; Scott, L.; Wells,
K. M.; Zhang-Plasket, F.; Nomura, S.; Hongu, M.; Koga, Y.
Process for the Preparation of Compounds Useful as Inhibitors
of SGLT. PCT Int. App. WO2009035969, 2009.
(1) Marsenic, O. Glucose control by the kidney: an emerging target in
diabetes. Am. J. Kidney Dis. 2009, 53, 875–883.
(2) Nishimura, M.; Naito, S. Tissue-specific mRNA expression pro-
files of human ATP-binding cassette and solute carrier transporter
superfamilies. Drug Metab. Pharmacokinet. 2005, 20, 452–477.
(3) Kanai, Y.; Lee, W. S.; You, G.; Brown, D.; Hediger, M. A.
The human kidney low affinity Naþ/glucose cotransporter
SGLT2: delineation of the major renal reabsorptive mechanism
for D-glucose. J. Clin. Invest. 1994, 93, 397–404.
(4) Zambrowicz, B. P.; Friedrich, G. A.; Buxton, E. C.; Lilleberg, S. L.;
Sands, A. T. Disruption and sequence identification of 2000 genes
in mouse embryonic stem cells. Nature 1998, 392, 608–611.
(5) Zambrowicz, B. P.; Friedrich, G. A. Comprehensive mammalian
genetics: history and future of gene trapping in the mouse. Int. J.
Dev. Biol. 1998, 42, 1025–1036.
(6) Van den Heuvel, L. P.; Assink, K.; Willemsen, M.; Monnens, L.
Autosomal recessive renal glucosuria attributable to a mutation in
the sodium glucose cotransporter (SGLT2). Hum. Genet. 2002, 111,
544–547.
(7) Calado, J.; Soto, K.; Clemente, C.; Correia, P.; Rueff, J. Novel
compound heterozygous mutations in SLC5A2 are responsible
for autosomal recessive renal glucosuria. Hum. Genet. 2004, 114,
314–316.
(8) Martin, M. G.;þTurk, E.; Lostao, M. P.; Kerner, C.; Wright, E. M.
Defects in Na /glucose cotransporter (SGLT1) trafficking and
function cause glucose-galactose malabsorption. Nat. Genet.
1996, 12, 216–220.
(9) Turk, D.; Zwbel, B.; Mundlos, S.; Dyer, J.; Wright, E. M.þGlucose/
galactose malabsorption caused by a defect in the Na /glucose
cotransporter. Nature 1991, 350, 354–356.
(10) Ehrenkranz, J. R. L.; Lewis, N. G.; Kahn, C. G.; Roth, J. Phlorizin:
a review. Diabetes Metab. Res. Rev 2005, 21, 31–38.
(11) Von Mering, J. Ueber kunstlichen Diabetes. Centralbl. Med. Wiss.
1886, xxii, 531.
(12) Washburn, W. N. Development of the renal glucose reabsorption
inhibitors: a new mechanism for the pharmacotherapy of diabetes
mellitus type 2. J. Med. Chem. 2009, 52, 1785–1794.
(13) Isaji, M. Sodium-glucose cotransporter inhibitors for diabetes.
Curr. Opin. Invest. Drugs 2007, 8, 285–292.
(27) Wright, E. M.; Turk, E. The sodium/glucose cotransport family
(14) Flint, A. A Treatise on the Principles and Practice of Medicine;
Lea and Brothers: Philadelphia, PA, 1886; p 929.
SLC5. Pfluegers Arch. 2004, 447, 510–518.
(28) A similar trend was reported in studies of C-arylglucosides:
Ellsworth, B. A.; Meng, W.; Patel, M.; Girotra, R. N.; Wu, G.;
Sher, P. M.; Hagan, D. L.; Obermeier, M. T.; Humphreys, W. G.;
Robertson, J. G.; Wang, A.; Han, S.; Waldron, T. L.; Morgan,
N. N.; Whaley, J. M.; Washburn, W. N. Aglycone exploration of
C-arylglucoside inhibitors of renal sodium-dependent glucose
transporter SGLT2. Bioorg. Med. Chem. Lett. 2008, 18, 4770–4773.
(29) The published selectivity of dapagliflozin for hSGLT1/hSGLT2 is
1200-fold (see ref 19). However, in our assays, we observed a 169-fold
selectivity for hSGLT2. See Supporting Information for further details
on the experimental methods used in this report.
(15) Fushimi, N.; Ito, F.; Isaji, M. Preparation of Glucopyranosyloxy-
benzylbenzene Derivatives As Inhibitors of Human SGLT2
(Sodium-Dependent Glucose Transporter 2), Medicinal Composi-
tion Containing the Same, Medicinal Use Thereof, and Intermedi-
ate for Production Thereof. PCT Int. Appl. WO2003011880, 2004.
(16) Fujikura, H.; Nishimura, T.; Katsuno, K.; Isaji, M. Preparation of
D-Glucose Derivatives as Human SGLT2 Inhibitors. PCT Int.
Appl. WO2004058790, 2004.
(17) Fushimi, N.; Yonekubo, S.; Muranaka, H.; Shiohara, H.;
Teranishi, H.; Shimizu, K.; Ito, F.; Isaji, M. Preparation of
Glucopyranoside CompoundsHaving Fused Heterocycle as SGLT
Inhibitors. PCT Int. Appl. WO2004087727, 2004.
(30) The full diastereoselective synthesis starting from commercially
available L-xylose is provided in the Supporting Information.